Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chuan xiong rhizoma aqueous extract is a water-based botanical preparation derived from the dried rhizome of *Ligusticum chuanxiong* Hort. (Sichuan lovage), a plant widely used in traditional Chinese medicine. The extract contains a complex profile of bioactive compounds, including phthalides (such as ligustilide), phenolic acids (notably ferulic acid), alkaloids, and polysaccharides. Preclinical research has demonstrated that the extract possesses neuroprotective, cardiovascular, and anti-tumor properties. Specifically, it has been investigated for its potential to enhance the efficacy of chemotherapeutic agents like temozolomide in treating melanoma brain metastases by modulating blood-brain barrier (BBB) integrity and exerting antioxidant effects on endothelial cells. It is primarily utilized as a research compound in preclinical models and is not currently an approved pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chuan xiong rhizoma aqueous extract.